Vaccine Development Boosted With 10 Mio. Euros at AFFiRiS AG

Noel Barrett appointed as additional member of the supervisory board

27-Jun-2016 - AFFiRiS AG has successfully completed its capital increase and raises an additional € 10m from existing investors and FCPB Affi GmbH. The Supervisory Board has appointed Günther Staffler as Chief Technology Officer. Noel Barrett has joined the Supervisory Board as of 15 June 2016. In an ...

Vaccine Specialist AFFiRiS AG successfully completes Financing Round

19-Jun-2015 - AFFiRiS AG has successfully completed its capital increase and raises an additional € 10m from existing investors. The Supervisory Board has appointed Oliver Siegel as Chief Executive Officer and Dr. Arne von Bonin as Chief Scientific Officer. Prof. Dr. Christoph Huber has joined the Supervisory ...

Breakthrough in Alzheimer's disease

AFFiRiS halted clinical progression in Alzheimer patients upon treatment with AD04 in a phase II clinical study

06-Jun-2014 - AFFiRiS AG released for the first time results of a clinical phase II study in Alzheimer patients of its proprietary compound AD04, a therapeutic drug against Alzheimer's disease. The results show an impressive therapeutic effect of AD04 and make it the first ever compound demonstrating clinical ...

EU support boosts development of vaccines against Parkinson's and Multiple System Atrophy

AFFiRiS leads consortium

30-Apr-2014 - An international consortium of top European research teams has received significant EU funding for the development of therapeutic vaccines against Parkinson's Disease (PD) and Multiple System Atrophy (MSA). Led by the Austrian biotech company AFFiRiS AG, the consortium will use a novel tandem ...

First clinical trial for the Parkinson´s vaccine starts in Vienna

07-Jun-2012 - AFFiRiS AG announced the start of the Phase I study of its Parkinson´s vaccine candidate PD01A. This vaccine represents the first agent worldwide aiming at disease modification of Parkinson´s rather than addressing symptomatic improvement only. PD01A targets a protein called alpha-Synuclein ...

AFFiRiS recruits Chief Business Officer

07-Dec-2011 - AFFiRiS AG announced today that Ali Alloueche is taking senior responsibility for their expanding business development activities. This new management position has been established as a result of the growing development pipeline of the Viennese biopharmaceutical company. As a member of the ...

The Michael J. Fox Foundation Awards AFFiRiS $1.5 Million for the Clinical Development of the First Parkinson’s Disease Vaccine

14-Oct-2011 - The Michael J. Fox Foundation (MJFF) announced that it has awarded $1.5 million to AFFiRiS AG for a clinical study of AFFITOPE® PD01, a first-of-its-kind Parkinson’s disease (PD) vaccine. AFFITOPE® PD01 targets and helps remove the alpha-synuclein protein, whose clumping is the pathological ...

AFFiRiS AG strengthens its development pipeline with the foundation of a Christian-Doppler-Laboratory

03-Jun-2011 - AFFiRiS AG is the industrial Partner of the newly-established Christian-Doppler-Laboratory for Cardiometabolic Immunotherapy. In partnership with the Medical University of Vienna the laboratory will work on basic research for the development of a vaccination therapy against Type 2 Diabetes and ...

AFFiRiS' Alzheimer's vaccination shows promising results

15-Mar-2011 - AFFiRiS' Alzheimer's vaccine candidate AD02 showed indicative evidence for potential efficacy in a phase I clinical trial. This was demonstrated by the analysis of the data from secondary clinical study endpoints. AFFiRiS AG previously announced that their Alzheimer vaccine candidate AD02 met the ...

AFFiRiS announces extension of its Alzheimer's disease vaccine development collaboration

07-Mar-2011 - AFFiRiS AG announced significant progress in their collaboration with GlaxoSmithKline Biologicals (GSK) for the development of an active vaccination programme against Alzheimer´s disease. While the lead vaccine candidate AD02 is currently in phase II clinical testing, two additional preclinical ...